Skip to main content

Advertisement

Log in

HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The relationship between low concentrations of high density lipoprotein cholesterol (HDL-C) and heightened risk for cardiovascular (CV) disease has been known for decades. Despite the consistent inverse relationship among epidemiological studies, the linkage between a residual low HDL-C among patients treated with statins and excess cardiovascular risk is less clearly established. Encouraging results from trials using niacin over the past 40 years have not been validated among more recent trials in patients taking contemporary anti-atherosclerotic therapy. Emerging evidence suggests that certain subsets of HDL particles may be more protective and/or more closely associated with CV disease than others, which may impact therapeutic benefits. Ongoing clinical trials will clarify whether raising HDL-C per se directly translates into a reduction in hard CV events. Until those results are available, the clinician is left with only weak evidence to support whether or not to target treatment of HDL-C with pharmacological therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707–14.

    Article  PubMed  CAS  Google Scholar 

  2. •• The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. Powerful summary of risk factor analysis in over 300,000 people without vascular disease from 68 long term prospective studies.

    Article  Google Scholar 

  3. Prospective Studies collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.

    Article  Google Scholar 

  4. • Vergeer M, Holenboom AG, Kastelein JJP, et al. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51:2058–73. Excellent review of HDL.

    Article  PubMed  CAS  Google Scholar 

  5. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target. A systematic review. JAMA. 2007;298:786–98.

    Article  PubMed  CAS  Google Scholar 

  6. Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Eng J Med. 2005;353:1252–60.

    Article  CAS  Google Scholar 

  7. Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease. An individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation. 2011;142:2056–64.

    Article  Google Scholar 

  8. Am S, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009;157:111–7.

    Article  Google Scholar 

  9. Alsheikh-Ali A, Lin J-L, Abourjaily P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499–501.

    Article  PubMed  CAS  Google Scholar 

  10. Cholesterol Treatment Trialists’ CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet. 2010;376:1670–81.

    Article  Google Scholar 

  11. Baigent C, Keech A, Kearney, et al. For the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2008;371:117–25.

    Article  PubMed  Google Scholar 

  12. Barter P, Gotto AM, La Rosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.

    Article  PubMed  CAS  Google Scholar 

  13. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153:800–8.

    PubMed  Google Scholar 

  14. • Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9. Provides evidence that in persons at risk for cardiovascular events obtaining a very low LDL-C eliminates the risk attributable to low HDL-C.

    Article  PubMed  CAS  Google Scholar 

  15. Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy. J Am Coll Cardiol. 2012;59:1521–8.

    Article  PubMed  CAS  Google Scholar 

  16. Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy. The Treating to New Targets (TNT) study. Circulation. 2012;125:1979–87.

    Article  PubMed  CAS  Google Scholar 

  17. •• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–61. European guidelines for lipid management.

    Article  PubMed  CAS  Google Scholar 

  18. Michos ED, Sibley CT, Baer JT, et al. Niacin and statin combination therapy for athersclerosis regression and prevention of cardiovascular disease events. J Am Coll Cardiol. 2012;59:2058–64.

    Article  PubMed  CAS  Google Scholar 

  19. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51:2032–57.

    Article  PubMed  CAS  Google Scholar 

  20. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871–82.

    PubMed  CAS  Google Scholar 

  21. • Rosenson RS, Brewer HB, Chapman MJ, et al. HDL Measures, particle heterogeneity, proposed nomenclature, and relationship to atherosclerotic events. Clin Chem. 2011;57(3):392–410. Excellent review of HDL and methods of measuring HDL particles.

    Article  PubMed  CAS  Google Scholar 

  22. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–33.

    Article  PubMed  CAS  Google Scholar 

  23. van der Steeg WA, Holme I, Boekholdt SM, et al. High-Density Lipoprotein Cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and Epic-Norfolk studies. J Am Coll Cardiol. 2008;51:634–42.

    Article  PubMed  Google Scholar 

  24. El Harchaoui K, Arsenault B, Franssen R, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150:84–93.

    PubMed  Google Scholar 

  25. Mackey RH, Greenland P, Goff DC, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60:508–16.

    Article  PubMed  CAS  Google Scholar 

  26. Navab M, Reddy ST, Lenten BJ, Fogelman AM. Nat Rev Cardiol. 2011;8(4):222–32.

    Article  PubMed  CAS  Google Scholar 

  27. • Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease. Prog Lip Res. 2012;51:314–24. Review of function and dysfunction of HDL particles.

    Article  CAS  Google Scholar 

  28. Navab M, Anantharamajah GM, Reddy ST, et al. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009;58(12):2711–7.

    Article  PubMed  CAS  Google Scholar 

  29. • Rader DJ, de Goma EM. Approach to the Patient with Extremely Low HDL-Cholesterol. J Clin Endocrinol Metab. 2012;97(10):3399–407. Summary of clinical approach to very low levels of HDL-C.

    Article  PubMed  CAS  Google Scholar 

  30. Chiesa G, Sirtori CR. Apolipoprotein A-1 Milano: current perspectives. Curr Opin Lipidol. 2003;14:159–63.

    Article  PubMed  CAS  Google Scholar 

  31. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesterol ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–88.

    Article  PubMed  CAS  Google Scholar 

  32. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120:2414–20.

    Article  PubMed  CAS  Google Scholar 

  33. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the actions of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149–64.

    Article  PubMed  CAS  Google Scholar 

  34. • Voight B, Pelos GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet. 2012;380:527–80. Demonstration that genetically raised HDL-C does not necessarily reduce risk.

    Google Scholar 

  35. Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endcrinol Metab. 2009;94(4):1264–73.

    Article  CAS  Google Scholar 

  36. Haase CL, Tybjaerg-Hansen A, Qayyum AA, et al. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: a Mendelian Randomization Study of HDL Cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248–56.

    Article  PubMed  CAS  Google Scholar 

  37. Roussell MA, Kris-Etherton P. Effects of lifestyle intervention on high density lipoprotein cholesterol levels. J Clin Lipidol. 2007;1:65–73.

    Article  PubMed  Google Scholar 

  38. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:1829–34.

    Article  PubMed  CAS  Google Scholar 

  39. Marmllot P, Munoz J, Patel S, et al. Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans. Metab Clin Exper. 2007;56:947–53.

    Article  Google Scholar 

  40. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81.

    Article  Google Scholar 

  41. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–55.

    Article  PubMed  CAS  Google Scholar 

  42. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2006;97(4):477–9.

    Article  PubMed  CAS  Google Scholar 

  43. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171:87–96.

    Article  PubMed  CAS  Google Scholar 

  44. Brown GB, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(1583–92):60–4.

    Google Scholar 

  45. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264(23):3013–7.

    Article  PubMed  CAS  Google Scholar 

  46. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.

    Article  PubMed  CAS  Google Scholar 

  47. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20–8.

    Article  PubMed  CAS  Google Scholar 

  48. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512 17.

    Article  Google Scholar 

  49. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(2):95–104.

    PubMed  Google Scholar 

  50. Villines TC, Stanek EJ, Devine PJ, et al. Michael Miller, The ARBITER 6-HALTS Trial. J Am Coll Cardiol. 2010;55:2721–6.

    Article  PubMed  Google Scholar 

  51. Shlipak MG, Chaput LA, Vittinghoff E, et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J. 2003;146(5):870–5.

    Article  PubMed  CAS  Google Scholar 

  52. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary event. N Engl J Med. 2007;357(21):2109–22.

    Article  PubMed  CAS  Google Scholar 

  53. Cannon CP. High-density lipoprotein cholesterol as the holy grail. JAMA. 2011;306(19):2153–5.

    Article  PubMed  CAS  Google Scholar 

  54. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012. doi:10.1056/NEJMoa1206797.

  55. •• The Aim-High Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. Surprising negative study of niacin plus statins which challenges the value of niacin.

    Article  Google Scholar 

  56. The AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The atherothrombosis intervention in metabolic syndrome with lowHDL/high triglycerides: impact on global health outcomes (AIM-HIGH). Am Heart J. 2011;161:471–477.e2.

    Article  Google Scholar 

  57. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(9):1672–8.

    Article  PubMed  CAS  Google Scholar 

  58. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118(12):1259–67.

    Article  PubMed  CAS  Google Scholar 

  59. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Melvyn Rubenfire.

Additional information

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubenfire, M., Brook, R.D. HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?. Curr Cardiol Rep 15, 349 (2013). https://doi.org/10.1007/s11886-013-0349-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-013-0349-3

Keywords

Navigation